Journal of IiME Volume 3 Issue 1 www.investinme.org DIETARY SUPPLEMENT HEALTHY CURB FOR REDUCING WEIGHT, GIRTH, BODY MASS, APPETITE AND FATIGUE WHILE IMPROVING BLOOD LIPID VALUES WITH NTFactor LIPID REPLACEMENT THERAPY Garth L. Nicolson, PhD, Rita Ellithrope, MD and Robert Settineri, MS The Institute for Molecular Medicine, Huntington Beach, CA 92647 The Tustin Longevity Center, Tustin, CA 92780 Sierra Productions, Irvine, CA 92606 ABSTRACT Often Chronic Fatigue Syndrome (CFS) patients have weight issues, and weight reduction regimens can increase fatigue. Therefore, we initiated a weight loss clinical trial using an all natural oral supplement mixture containing an FDA-approved amaylase inhibitor plus NTFactorTM, which is known to safely reduce fatigue in aged subjects,1 chronic fatigue2 and CFS.3 The objective was to see if subjects could safely lose weight without increasing appetite and fatigue and without changing eating or exercise patterns or using drugs, herbs or caffeine. A 2-month open label clinical trial was initiated with 30 patients who used an oral mixture (Healthy CurbTM) of amaylase inhibitor (500 mg white kidney bean extract) plus 500 mg of NTFactorTM 30 min before each meal. Weight and measurements were taken weekly, appetite was assessed4 and fatigue was determined using the Piper Fatigue Scale.5 Sixty-three percent of the participants lost an average of 6 pounds along with 2.5 and 1.5 inch reductions in waist and hip circumference, respectively, and the entire group of participants lost an average of 3 pounds with average reductions of 1.5 and 1 inch waist and hip circumference, respectively. Participants experienced gradual and consistent weight loss along with waist and hip, body mass index (BMI) and basal metabolic rate (BMR) reductions during the entire trial. There was a 44% reduction in overall hunger with reduced cravings for sweets; therefore, notable appetite suppression occurred. Using the Piper Fatigue Scale the entire test group showed an average of 23% decrease in overall fatigue. Blood lipid profiles generally improved, suggesting improved cardiovascular health, and no adverse effects were noted clinically or found in blood chemistries. Conclusions: The vast majority of the subjects in this trial lost weight, showed decreased waist and hip measurements and overall body mass. Their overall fatigue was reduced, and they experienced marked appetite suppression. The product was completely safe and void of any side effects and was extremely Invest in ME (Charity Nr. 1114035) Professor Garth Nicolson The Institute for Molecular Medicine, P.O. Box 9355, S. Laguna Beach, California 92652. Tel: 949-715-7958; Email: gnicolson@immed.org; Website: www.immed.org ME RESEARCH “Many studies have found that the immune system appears to be in a state of chronic activation (and) genes that control the activation of the immune system are abnormally expressed in patients with this illness. A number of studies have shown that there probably are abnormalities of energy metabolism in patients with this illness”. Professor Anthony Komaroff of the Harvard Medical School Page 39/76
40 Publizr Home